Skip to main content
MedPathMedPath Home
Clinical Trials/IRCT20240213060992N1
IRCT20240213060992N1
Not yet recruiting
Phase 4

Comparing the effect of low dose and standard dose Cyproheptadine on BMI enhancement in children aged 2-10 and evaluation of its side effects

Shahre-kord University of Medical Sciences0 sites90 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditionsthinness.

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
thinness.
Sponsor
Shahre-kord University of Medical Sciences
Enrollment
90
Status
Not yet recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Interventional
Sex
All

Investigators

Sponsor
Shahre-kord University of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • •Consent of the child's guardian to participate in the study
  • •Being aware and vigilant of the guardian of the child
  • •Age 2 to 9 years and 6 months at the first visit
  • •BMI Z\-score is less than \-2 standard deviations in the BMI table according to age and sex of the CDC, which is set based on 15day intervals.

Exclusion Criteria

  • •Celiac disease, Crohn's disease, sensitivity to cow's protein, hypothyroidism, hyperthyroidism, congenital megacolon, eosinophilic gastroenteritis, cystic fibrosis and any disease that causes malabsorption.
  • •Allergy to antihistamines
  • •Consumption of other appetite stimulants and multivitamins and zinc in the study
  • •Treatment with growth hormone, gonadotropin\-releasing hormone analog, aromatase inhibitors, recombinant human\-like growth factor and androgen in the study
  • •Entering stage 1 of puberty including the enlargement of testicles in boys, growth of pubic hair in boys, breast enlargement in girls

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
Old drug in new dose: Olanzapine in chemotherapy induced nausea & vomiting, does dose matters?
CTRI/2020/02/023589Sandip Mukhopadhyay100
Recruiting
Phase 3
Thalidomide for patients with Thalassemia majorHealth Condition 1: D561- Beta thalassemia
CTRI/2022/05/042781Pahuja trust for blood disorders
Completed
Phase 3
Evaluating the effect of low dose vs moderate dose clofibrate on decreasing serum bilirubin in healthy full term neonateseonatal jaundice.P59.9 Neonatal jaundice, unspecified
IRCT2012092910933N1Hamadan University of Medical Sciences132
Not yet recruiting
Not Applicable
A study to compare the effect of low dose versus conventional dose intrathecal fentanyl with hyperbaric bupivacaine on the block characteristics in parturient undergoing caesarean section under spinal anaesthesia
CTRI/2021/08/035932airikyengbam Sheityajit Roy
Completed
Phase 2
Efficacy of oral low-dose Isotretinoin in the treatment of acne vulgarisAcne vulgaris.Acne vulgaris
IRCT2015061722780N1Vice chancellor for research of Isfahan University of Medical Sciences60